Author

Alaina Burgess

h-index 0 View on Semantic Scholar

We have 2 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease 2251383

GNTI-932 is a novel, hypoimmune, antigen-specific, off-the-shelf immunotherapy for restoring tolerance in IBD, designed to be scalable and affordable for widespread use.

Martina Sassone-Corsi, J. Yam, Abigail Doherty et al. · Journal of Immunology · 0 citations

Jul 2026

An allogeneic CD19 targeted Engineered Treg approach for treating B cell mediated autoimmune diseases 2260315

GNTI-350 can safely achieve a durable immune reset and may provide superior therapeutic benefit over CAR-T approaches to patients with B cell—driven autoimmune diseases.

P. Zarin, Chris B. Moore, Travis Drow et al. · Journal of Immunology · 0 citations